US0198181036 - Common Stock
ALLOVIR INC
NASDAQ:ALVR (5/6/2024, 7:00:00 PM)
After market: 0.8 -0.01 (-0.79%)0.8064
+0.01 (+1.05%)
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2020-07-30. The firm is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes posoleucel, ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, posoleucel, is a multi- VST therapy targeting six viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), JC virus (JCV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.
ALLOVIR INC
1100 Winter Street
Waltham MASSACHUSETTS 02142
P: 16174332605
CEO: David Hallal
Employees: 106
Website: https://www.allovir.com
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class...
WHY: NEW YORK, NY - (NewMediaWire) - March 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR stock results show that AlloVir missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AlloVir (NASDAQ:ALVR) just reported results for the fourth quarter of 2023.Allo...
Here you can normally see the latest stock twits on ALVR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: